# Expanded Access to Veliparib

> **NCT03123211** · — · NO_LONGER_AVAILABLE · sponsor: **AbbVie**

## Conditions studied

- Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
- Triple Negative Breast Cancer (TNBC)
- High Grade Serous Ovarian Cancer
- Patients Requiring Veliparib Suspension Formulation

## Interventions

- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT03123211
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123211, "Expanded Access to Veliparib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03123211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*